THC Cell Signaling Rankings Did Not Establish Different Internalization Effects
A cell study found clearer differences among cannabinoids on a signaling assay than on receptor internalization. Ranking the sample estimates did not make every apparent difference statistically supported.
Two responses in engineered cells
Researchers used mouse pituitary-derived cells expressing fluorescently tagged human CB1 receptors. They compared THC, anandamide and synthetic agonists on GIRK-related membrane-potential responses and receptor internalization. Human receptor expression did not turn the preparation into a human clinical study.
The null comparisons mattered
Selected signaling potency and efficacy comparisons differed significantly. The internalization results did not provide the same statistically supported separation, and within-cannabinoid comparisons between the measured pathways also did not establish significant differences. Visual rank orders therefore needed the accompanying uncertainty.
What the assay did not exclude
The investigators noted that GIRK responses were not tested in cells lacking CB1, leaving possible non-CB1 contributions unresolved. Engineered expression, host cells and assay timing also constrain interpretation. The experiment did not prove biased signaling in cannabis users, quantify human tolerance or determine impairment. Its contribution is an analytical distinction between estimated ordering, statistical evidence and the specific cellular response being measured.
Related analysis: evaluating cannabis tolerance claims.
Primary research
Comparing CB1 receptor GIRK channel responses to receptor internalization using a kinetic imaging assay. Scientific reports (2024). DOI: 10.1038/s41598-024-68451-2.
